Novartis India surges 7% as board mulls share buyback
So far in 2017, the stock under-performed the market by falling 24% as compared to 22% rise in the S&P BSE Sensex till Wednesday.
)
premium
Novartis is addressing the pricing question with a new type of agreement: For patients whose care is covered by the US govt programmes, the company will only get paid if patients show signs that the treatment is working within a month | Photo: istock
Novartis India surged 7% to Rs 697 on BSE in early morning trade after the pharmaceuticals company said that the board will meet on Monday, September 25, 2017 to consider a proposal for buyback of the company's equity shares.